NR2F1 and non-small cell lung carcinoma: <b>Conclusions:</b> Collectively, our findings delineate a <i>NAS1</i>/<i>NR2F1</i>/<i>TGFB1</i>/NF-κB signaling axis critical for cisplatin resistance in NSCLC, revealing a potential therapeutic target for overcoming platinum resistance.